Next Phase Newsletter

A healthcare company headquartered in the US with multiple offices globally has expanded to multiple subsidiaries that focus on different indications of unmet need. The firm is currently seeking promising assets to license and acquire, to supplement their existing asset portfolio and continue to expand to new disease areas. The firm is open to global opportunities.

The firm is only interested in therapeutics opportunities and is generally open to all indications and modalities. The firm has a preference for clinical stage assets, but may consider pre-clinical assets on occasion.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm specializing in technologies, financials and healthcare industries is backed by an investment and hospital management team with more than 100 years and 80 years respectively of combined professional experiences.

The firm invests in three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with the firm’s domestic and foreign hospital & medical network.

The firm does not have management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Life Sciences investment firm typically allocates up to $4M per initial investment. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach. The firm typically syndicates with major US venture capital firms. The firm is currently seeking new opportunities in the US, Canada, and Western Europe.

The firm puts 60% focus on therapeutics and 40% on medical devices, diagnostics and digital health. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor 20% interest in early-stage breakthrough bioengineering platforms with strong management teams. In medtech and digital health, the firm seeks to provide growth funding in technologically de-risked stories in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, medical services facilities and health tech, and biosimilars/generics/reformulations are not of interest.

The firm focuses on five key disease areas: oncology, autoimmune diseases, anti-infectives, CNS/pain, and women’s health. In oncology and autoimmune diseases, the firm seeks therapies with novel mechanisms of action, human data and signs of efficacy, and it also considers new generation molecular diagnostics technologies. In anti-infectives, the firm is considering early stage assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and a clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.

The firm is looking for high-caliber serial entrepreneurs with an unmatched track-record of success and strong credibility. The firm does not typically take a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe focuses on investing in digital health, devices and diagnostics technologies. Though an early investor, the firm looks for companies that have some proof of concept data. The firm will consider investments in North America and Europe. The firm generally looks to invest between 100K-2M EUR in their portfolio companies.

The firm will invest in digital health as well as diagnostics and devices as well as regenerative medicine technologies. For diagnostics and devices, the firm prefers companies with a digital component. In addition, the firm prefers devices without complex regulatory requirements. The firm is agnostic with regards to indication.

The firm is willing to lead or co-invest. Generally, the firm prefers to have a board or an observer seat after investing. Within the life sciences, the firm prefers to invest in teams with industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital firm with offices in USA and Western Europe invests from an evergreen fund. The firm interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $10 million over the life of an investment.  The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments; the fund’s allocations are ‘no strings attached’. The firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities beyond the corporate’s core areas of business.  The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology), but will also consider opportunities in other indication areas that lie outside of the corporate’s present core therapeutic fields. Areas in which the parent company has strength, such as respiratory disorders and diabetes, will generally not receive investment from the firm. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance to the parent company. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The investment division of a biotech company is solely dedicated to the identification and success of early-stage, biotech start-ups for the firm’s incubation and investment platforms. The firm’s commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

The firm invests globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. Leveraging the firm’s experience and technical advantages in the field of novel drug R&D, the firm provides both cash and in-kind services (EFS) for their investment. Additionally, based on the need, the firm also offers value-added services in operation and logistic support, BD and Financing assistance, etc. to accelerate the growth of its portfolio companies. The firm can allocate from $500,000 to $5,000,000 of equity capital or convertible notes in seed or Series A.

The firm focuses on novel, preclinical therapeutics and is agnostic to indication, modality and geography. The firm is currently most interested in small molecule first-in-class drugs but is open to considering all drug types. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Diagnostics, Medical Devices, or Healthcare IT companies.

The firm does not have specific requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Europe is actively seeking innovative investment opportunities with high potential for growth. With their latest fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm. With this fund, the firm seeks to make 18-20 investments with initial investment sizes in the range of $3-10M. The firm will focus on companies that are based in USA, Canada, and Western Europe, but may review those from other geographies on a case by case basis.

The firm is most interested in life science companies with a digital component. This includes healthcare IT/digital health, utilization of AI/machine learning for drug discovery, genomics, precision medicine, etc. The firm is open to medical devices or diagnostics that have a digital component. In particular, the firm is most interested in technologies that are dedicated to the treatment of chronic disorders and lead to improved outcomes and lower care costs in hospital systems. The firm will not consider traditional biopharmaceutical modalities.

The firm carefully evaluates investment opportunities based on the quality and experienced of the management team as well as market opportunity. The firm is open to both leading and co-investing, and in the former case will seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.